Ascentage Pharma Announces the Fifth Orphan Drug Designation Granted to Bcl-2 Inhibitor APG-2575 by the US FDA, and the Tenth Obtained by the Company
This is not a CAPTIS article. Originally, it was published here.
The Future of Home Buying Arrives in PhiladelphiaNLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Of...